Pirepemat

Pirepemat
Clinical data
Other names	IRL-752; IRL752
Pharmacokinetic data
Elimination half-life	3.7–5.2 hours
Identifiers
	IUPAC name (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine;
CAS Number	1227638-29-0;
PubChem CID	135381565;
DrugBank	DB19165;
ChemSpider	115009507;
UNII	JS88RK5NOI;
ChEMBL	ChEMBL5095193;
Chemical and physical data
Formula	C11H13F2NO
Molar mass	213.228 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CO[C@@]1(CCNC1)C2=C(C(=CC=C2)F)F;
	InChI InChI=1S/C11H13F2NO/c1-15-11(5-6-14-7-11)8-3-2-4-9(12)10(8)13/h2-4,14H,5-7H2,1H3/t11-/m1/s1; Key:LJNFYMMXCXGFCP-LLVKDONJSA-N;

Pirepemat (INNTooltip International Nonproprietary Name; developmental code name IRL752 or IRL-752) is a drug which is under development for the prevention of falls in people with Parkinson's disease and Parkinson's disease dementia.^[2]^[3]^[4]^[5]^[1]^[6] It has been referred to as a "nootrope" (i.e., nootropic or cognitive enhancer).^[7]

^ ^a ^b Rein-Hedin E, Sjöberg F, Waters S, Sonesson C, Waters N, Huss F, et al. (December 2021). "First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers". Clin Pharmacol Drug Dev. 10 (12): 1485–1494. doi:10.1002/cpdd.959. PMID 34118179.
^ Maher S, Donlon E, Mullane G, Walsh R, Lynch T, Fearon C (April 2024). "Treatment of Apathy in Parkinson's Disease and Implications for Underlying Pathophysiology". J Clin Med. 13 (8): 2216. doi:10.3390/jcm13082216. PMC 11051068. PMID 38673489.
^ Phillips O, Ghosh D, Fernandez HH (May 2023). "Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions". Current Treatment Options in Neurology. 25 (5). Springer Science and Business Media LLC: 93–119. doi:10.1007/s11940-023-00749-4. ISSN 1092-8480.
^ Wolff A, Schumacher NU, Pürner D, Machetanz G, Demleitner AF, Feneberg E, et al. (June 2023). "Parkinson's disease therapy: what lies ahead?". J Neural Transm (Vienna). 130 (6): 793–820. doi:10.1007/s00702-023-02641-6. PMC 10199869. PMID 37147404.
^ Hjorth S, Waters S, Waters N, Tedroff J, Svensson P, Fagerberg A, et al. (September 2020). "(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent". J Pharmacol Exp Ther. 374 (3): 404–419. doi:10.1124/jpet.120.000037. hdl:10454/17970. PMID 32605972.
^ Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, et al. (June 2020). "A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia". Mov Disord. 35 (6): 1046–1054. doi:10.1002/mds.28020. PMID 32198802.
^ "Proposed INN: List 123 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (2). 2020.

[Rein-HedinSjöbergWaters2021-1] Rein-Hedin E, Sjöberg F, Waters S, Sonesson C, Waters N, Huss F, et al. (December 2021). "First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers". Clin Pharmacol Drug Dev. 10 (12): 1485–1494. doi:10.1002/cpdd.959. PMID 34118179.

[MaherDonlonMullane2024-2] Maher S, Donlon E, Mullane G, Walsh R, Lynch T, Fearon C (April 2024). "Treatment of Apathy in Parkinson's Disease and Implications for Underlying Pathophysiology". J Clin Med. 13 (8): 2216. doi:10.3390/jcm13082216. PMC 11051068. PMID 38673489.

[PhillipsGhoshFernandez2023-3] Phillips O, Ghosh D, Fernandez HH (May 2023). "Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions". Current Treatment Options in Neurology. 25 (5). Springer Science and Business Media LLC: 93–119. doi:10.1007/s11940-023-00749-4. ISSN 1092-8480.

[WolffSchumacherPürner2023-4] Wolff A, Schumacher NU, Pürner D, Machetanz G, Demleitner AF, Feneberg E, et al. (June 2023). "Parkinson's disease therapy: what lies ahead?". J Neural Transm (Vienna). 130 (6): 793–820. doi:10.1007/s00702-023-02641-6. PMC 10199869. PMID 37147404.

[HjorthWatersWaters2020-5] Hjorth S, Waters S, Waters N, Tedroff J, Svensson P, Fagerberg A, et al. (September 2020). "(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent". J Pharmacol Exp Ther. 374 (3): 404–419. doi:10.1124/jpet.120.000037. hdl:10454/17970. PMID 32605972.

[SvenningssonOdinDizdar2020-6] Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, et al. (June 2020). "A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia". Mov Disord. 35 (6): 1046–1054. doi:10.1002/mds.28020. PMID 32198802.

[WHO2020-7] "Proposed INN: List 123 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (2). 2020.

[1]

[2]

[3]

[4]

[5]

[6]

[7]